PRO MEDICUS Aktie

 

Another US contract adds to a growth story I think still has a long way to run. The post Should I buy Pro Medicus shares after its big news? appeared first on The Motley Fool Australia....

Pro Medicus shares are in the spotlight after announcing a major US contract win for its Visage cloud imaging platform. The post Pro Medicus signs A$24M US deal appeared first on The Motley Fool Australia....

The shares have fallen hard, but the business itself continues to grow at an impressive rate. The post Down 44%: Will you regret not buying Pro Medicus shares? appeared first on The Motley Fool Australia....

Pro Medicus and Droneshield are both popular ASX growth shares, but only one stands out for quality and momentum right now. The post Droneshield vs Pro Medicus: Which is the better ASX growth stock right now? appeared first on The Motley Fool Australia....

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy in October (and why). The post CSL vs Pro Medicus: Which ASX healthcare share is better? appeared first on The Motley Fool Australia....

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago? The post $10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth… appeared first on The Motley Fool Australia....

Codan and Pro Medicus are both ASX growth stars, but which one offers better value for investors right now? I weigh up the numbers. The post Codan vs Pro Medicus: Which ASX growth stock is better value? appeared first on The Motley Fool Australia....

We compare Cochlear and Pro Medicus after major share price declines. See which ASX healthcare stock I'd lean towards today. The post Cochlear vs Pro Medicus: Which beaten-down ASX healthcare share is the better buy today? appeared first on The Motley Fool Australia....

A leading expert believes Pro Medicus shares are well-place to rebound. The post Down 43%! 4 reasons to buy the BIG dip in Pro Medicus shares today appeared first on The Motley Fool Australia....

Let's start the week with some fresh ratings from the experts.  The post Buy, hold, sell: Pro Medicus, BHP, CBA shares appeared first on The Motley Fool Australia....

A decade turned $10,000 into roughly $346,000. The post How much would $10,000 invested 10 years ago in Pro Medicus shares be worth today? appeared first on The Motley Fool Australia....

This business still delivers healthy profit growth. Does it have a good future ahead? The post How much could the Pro Medicus share price rise in the next year? appeared first on The Motley Fool Australia....

Experts reveal new ratings on 3 ASX 200 sector heavyweights as earnings season continues. The post Buy, hold, sell: Pro Medicus, Fortescue, CBA shares appeared first on The Motley Fool Australia....

Healthcare outperformed while the ASX 200 weakened as earnings season continued last week. The post ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus appeared first on The Motley Fool Australia....

Pro Medicus' (ASX: PME) wholly-owned US subsidiary Visage Imaging has signed a…...

Pro Medicus, Guzman Y Gomez, and James Hardie shares are creating a buzz on Friday. But why? The post Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday appeared first on The Motley Fool Australia....

The tech stock has announced another contract win this morning. The post Pro Medicus signs A$25m US contract: What it means for investors appeared first on The Motley Fool Australia....

These are three ASX healthcare shares I would be happy to own for years. The post Why I'd buy CSL, Cochlear, and Pro Medicus shares appeared first on The Motley Fool Australia....

Here's Bell Potter's latest price targets. The post Healthcare results wrap: Are Cogstate and Pro Medicus shares a buy, hold or sell? appeared first on The Motley Fool Australia....

CANBERA (dpa-AFX) - Pro Medicus Ltd. (PMCUF, PME.AX), an Australian health imaging company, reported Tuesday significantly higher profit in fiscal 2026, benefited mainly by revenue growth. Further......